casno. : CAS 98319-26-7
Finasteride is a 4-azasteroid compound, which is a specific inhibitor of intracellular enzyme type II 5a reductase in the process of testosterone metabolism to stronger dihydrotestosterone. Benign prostatic hyperplasia, or BPH, depends on the transformation of testosterone into dihydrotestosterone in the prostate. This drug can effectively reduce dihydrotestosterone in blood and prostate. Finasteride has no affinity for androgen receptors.
In a long-term efficacy and safety study of this drug (PLESS), 3016 patients with moderate to severe symptoms of prostatic hyperplasia who took this drug for 4 years were evaluated for the treatment of the urinary system related to prostatic hyperplasia (surgical intervention), such as transurethral resection of prostate and other prostatectomy, or acute urinary retention requiring catheter insertion. In this double-blind, randomized, placebo-controlled multicenter study, this drug treatment reduced the overall risk of urinary system disposal by 51%, accompanied by significant and continuous prostate volume reduction, as well as continuous maximum urinary flow rate increase and symptom improvement.